Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. Academic Article uri icon

Overview

abstract

  • BACKGROUND: The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial carcinoma of the bladder (MIBC) treated with cystectomy alone is approximately 50%. Platinum based neoadjuvant chemotherapy (NAC) plus cystectomy results in a marginal 5-10% increase in 5-year CSS in MIBC. Interestingly, responders to NAC (

publication date

  • July 31, 2015

Research

keywords

  • Biomarkers, Tumor
  • Cisplatin
  • Muscle Neoplasms
  • Neoadjuvant Therapy
  • Urinary Bladder Neoplasms

Identity

PubMed Central ID

  • PMC4521868

Scopus Document Identifier

  • 84942116726

Digital Object Identifier (DOI)

  • 10.1371/journal.pone.0131245

PubMed ID

  • 26230923

Additional Document Info

volume

  • 10

issue

  • 7